STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

SPL	Change of Director's Interest Notice		23/04/12	31.8KB	Share
SPL	Appendix 3B		16/04/12	101.08KB	Share
SPL	Shareholder Update April 2012		16/04/12	1.61MB	Share
SPL	FORM 604 CHANGE OF INTERESTS OF SUB HOLDER		22/03/12	72.94KB	Share
SPL	SPL Commences pivotal phase 3 VivaGel BV treatment trials	PRICE SENSITIVE	22/03/12	193.59KB	Share
SPL	Appendix 3B		13/03/12	101.38KB	Share
SPL	Correction - Initial Director's Interest Notice		13/03/12	104.58KB	Share
SPL	Initial Director's Interest Notice		13/03/12	103.99KB	Share
SPL	International licensing expert Peter Turvey joins SPL Board		09/03/12	124.98KB	Share
SPL	Starpharma presenting at Citi investment conference London		06/03/12	1.3MB	Share
SPL	Change of Director's Interest Notice		29/02/12	32.82KB	Share
SPL	Change of Director's Interest Notice		29/02/12	35.39KB	Share
SPL	Appendix 3B		29/02/12	73.3KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	20/02/12	639.37KB	Share
SPL	SPL's dendrimers improve efficacy of docetaxel in animals	PRICE SENSITIVE	01/02/12	189.28KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/12	123.68KB	Share
SPL	Appendix 3B		24/01/12	97.69KB	Share
SPL	Appendix 3B		24/01/12	97.48KB	Share
SPL	Change in substantial holding		12/01/12	58.92KB	Share
SPL	SPL receives FDA Special Protocol Assessment for BV Phase 3	PRICE SENSITIVE	11/01/12	78KB	Share
SPL	Appendix 3B		22/12/11	97.48KB	Share
SPL	Change of Director's Interest Notice		21/12/11	109.06KB	Share
SPL	Shareholder Update		20/12/11	628.03KB	Share
SPL	Change of Director's Interest Notice x3		19/12/11	153.19KB	Share
SPL	Starpharma's drug delivery program with Lilly advances	PRICE SENSITIVE	19/12/11	101.24KB	Share
SPL	Appendix 3B		14/12/11	73.4KB	Share
SPL	SPP Allotment		14/12/11	99.69KB	Share
SPL	FORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER		13/12/11	49.57KB	Share
SPL	Change of Director's Interest Notice		12/12/11	109.02KB	Share
SPL	SPP closes heavily overscribed, completing $35m financing		08/12/11	115.38KB	Share
SPL	Change of Director's Interest Notice		06/12/11	109.08KB	Share
SPL	Initial Director's Interest Notice		06/12/11	215.6KB	Share
SPL	Appendix 3B		30/11/11	73.16KB	Share
SPL	Form 604 lodged 21/11/11 to be disregarded		25/11/11	98.1KB	Share
SPL	Change of Director's Interest Notice		25/11/11	32.11KB	Share
SPL	Appendix 3B		25/11/11	74.7KB	Share
SPL	FORM 603 INITIAL SUB FOLDER		24/11/11	28.99KB	Share
SPL	Share Purchase Plan offer documents		22/11/11	400.1KB	Share
SPL	Change in substantial holding		21/11/11	115.25KB	Share
SPL	Cleansing Statement		21/11/11	116.18KB	Share
SPL	Starpharma secures European (EMA) agreement on BV Phase 3	PRICE SENSITIVE	21/11/11	103.06KB	Share
SPL	Appendix 3B		21/11/11	74.39KB	Share
SPL	Starpharma completes A$32 million placement, SPP to follow	PRICE SENSITIVE	16/11/11	125.11KB	Share
SPL	Trading Halt	PRICE SENSITIVE	14/11/11	52.38KB	Share
SPL	Results of Meeting		10/11/11	37.18KB	Share
SPL	AGM Chairman's address and CEO presentation		10/11/11	1.67MB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/11	165.23KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		10/10/11	595.26KB	Share
SPL	Starpharma secures FDA agreement on BV treatment Phase 3	PRICE SENSITIVE	10/10/11	150.94KB	Share
SPL	Ms Zita Peach appointed non-executive director		26/09/11	138.5KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB ATT DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSP	SandP Indices Announces September Quarterly Rebalance	PRICE SENSITIVE	09/09/11	62.33KB	Share
SPL	Appendix 3B		07/09/11	82.8KB	Share
SPL	Starpharma Elevated to Standard and Poor's ASX 300 Index		06/09/11	145.28KB	Share
SPL	Starpharma presents at Macquarie investor event		31/08/11	2.22MB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	29/08/11	1.48MB	Share
SPL	Appendix 3B		24/08/11	82.8KB	Share
SPL	GSK awarded funds for dermal treatment with SPL's dendrimers	PRICE SENSITIVE	22/08/11	47.49KB	Share
ANN +SPL	SPL terminates Reckitt agreement and signs with Ansell	PRICE SENSITIVE	17/08/11	196.49KB	Share
SPL	SPL Commences VivaGel Bacterial Vaginosis Prevention Study	PRICE SENSITIVE	15/08/11	173.03KB	Share
SPL	Appendix 3B		09/08/11	67.61KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	28/07/11	155.22KB	Share
SPL	Shareholder Update July 2011		26/07/11	1.15MB	Share
SPL	Partners of bacterial vaginosis at increased risk of HIV		19/07/11	142.16KB	Share
SPL	Appendix 3B		13/07/11	70.35KB	Share
SPL	Starpharma advances agrochemical program	PRICE SENSITIVE	12/07/11	243.24KB	Share
SPL	Advances leading cancer therapeutic in drug delivery program	PRICE SENSITIVE	29/06/11	251.98KB	Share
SPL	Appendix 3Z		20/06/11	102.8KB	Share
SPL	Resignation of Director		20/06/11	133.48KB	Share
SPL	Appendix 3B		14/06/11	62.4KB	Share
SPL	Starpharma Audio Broadcast		24/05/11	88.08KB	Share
SPL	VivaGel Demonstrates Efficacy in Bacterial Vaginosis	PRICE SENSITIVE	23/05/11	172.31KB	Share
SPL	Appendix 3B		19/05/11	62.53KB	Share
SPL	VivaGel Coated Condom Licence Agreement with Okamoto Japan	PRICE SENSITIVE	10/05/11	188.75KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/11	153.36KB	Share
SPL	Appendix 3B		01/04/11	62.41KB	Share
SPL	Change in substantial holding		29/03/11	86.61KB	Share
SPL	Appendix 3B		29/03/11	61.77KB	Share
SPL	Shareholder Update March 2011		29/03/11	530.89KB	Share
SPL	Completes enrolment for Phase 2 study of VivaGel for BV	PRICE SENSITIVE	23/03/11	149.02KB	Share
SPL	Appendix 3B		22/03/11	64.2KB	Share
SPL	Change in substantial holding		18/03/11	85.49KB	Share
SPL	SPL presents at ASX Emerging Growth Conference		10/03/11	2.08MB	Share
SPL	Appendix 3B		07/03/11	69.81KB	Share
SPL	SPL to expand agricultural program through $250,000 funding	PRICE SENSITIVE	03/03/11	140.04KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/11	705.75KB	Share
SPL	Appendix 3B		17/02/11	65.05KB	Share
SPL	Change in substantial holding		16/02/11	86.23KB	Share
SPL	Appendix 3B		14/02/11	62.67KB	Share
SPL	Response to ASX Query	PRICE SENSITIVE	09/02/11	91.14KB	Share
SPL	Appendix 3B		03/02/11	67.64KB	Share
SPL	Appendix 3B		01/02/11	65.34KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/11	59.55KB	Share
SPL	Change of Director's Interest Notice		10/01/11	32.5KB	Share
SPL	Appendix 3B		10/01/11	65.93KB	Share
SPL	Appendix 3B		23/12/10	67.12KB	Share
SPL	Appendix 3B		20/12/10	68.29KB	Share
SPL	Revised Securities Trading Policy		16/12/10	72.21KB	Share
SPL	Change of Director's Interest Notice - Dr J Fairley		15/12/10	17.03KB	Share
SPL	Appendix 3B		10/12/10	67.8KB	Share
SPL	Appendix 3B		02/12/10	67.7KB	Share

SPLChange of Director's Interest Notice
23/04/12		31.8KB	Share
SPLAppendix 3B
16/04/12		101.08KB	Share
SPLShareholder Update April 2012
16/04/12		1.61MB	Share
SPLFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
22/03/12		72.94KB	Share
SPLSPL Commences pivotal phase 3 VivaGel BV treatment trials
22/03/12	PRICE SENSITIVE	193.59KB	Share
SPLAppendix 3B
13/03/12		101.38KB	Share
SPLCorrection - Initial Director's Interest Notice
13/03/12		104.58KB	Share
SPLInitial Director's Interest Notice
13/03/12		103.99KB	Share
SPLInternational licensing expert Peter Turvey joins SPL Board
09/03/12		124.98KB	Share
SPLStarpharma presenting at Citi investment conference London
06/03/12		1.3MB	Share
SPLChange of Director's Interest Notice
29/02/12		32.82KB	Share
SPLChange of Director's Interest Notice
29/02/12		35.39KB	Share
SPLAppendix 3B
29/02/12		73.3KB	Share
SPLHalf Yearly Report and Accounts
20/02/12	PRICE SENSITIVE	639.37KB	Share
SPLSPL's dendrimers improve efficacy of docetaxel in animals
01/02/12	PRICE SENSITIVE	189.28KB	Share
SPLAppendix 4C - quarterly
30/01/12	PRICE SENSITIVE	123.68KB	Share
SPLAppendix 3B
24/01/12		97.69KB	Share
SPLAppendix 3B
24/01/12		97.48KB	Share
SPLChange in substantial holding
12/01/12		58.92KB	Share
SPLSPL receives FDA Special Protocol Assessment for BV Phase 3
11/01/12	PRICE SENSITIVE	78KB	Share
SPLAppendix 3B
22/12/11		97.48KB	Share
SPLChange of Director's Interest Notice
21/12/11		109.06KB	Share
SPLShareholder Update
20/12/11		628.03KB	Share
SPLChange of Director's Interest Notice x3
19/12/11		153.19KB	Share
SPLStarpharma's drug delivery program with Lilly advances
19/12/11	PRICE SENSITIVE	101.24KB	Share
SPLAppendix 3B
14/12/11		73.4KB	Share
SPLSPP Allotment
14/12/11		99.69KB	Share
SPLFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER
13/12/11		49.57KB	Share
SPLChange of Director's Interest Notice
12/12/11		109.02KB	Share
SPLSPP closes heavily overscribed, completing $35m financing
08/12/11		115.38KB	Share
SPLChange of Director's Interest Notice
06/12/11		109.08KB	Share
SPLInitial Director's Interest Notice
06/12/11		215.6KB	Share
SPLAppendix 3B
30/11/11		73.16KB	Share
SPLForm 604 lodged 21/11/11 to be disregarded
25/11/11		98.1KB	Share
SPLChange of Director's Interest Notice
25/11/11		32.11KB	Share
SPLAppendix 3B
25/11/11		74.7KB	Share
SPLFORM 603 INITIAL SUB FOLDER
24/11/11		28.99KB	Share
SPLShare Purchase Plan offer documents
22/11/11		400.1KB	Share
SPLChange in substantial holding
21/11/11		115.25KB	Share
SPLCleansing Statement
21/11/11		116.18KB	Share
SPLStarpharma secures European (EMA) agreement on BV Phase 3
21/11/11	PRICE SENSITIVE	103.06KB	Share
SPLAppendix 3B
21/11/11		74.39KB	Share
SPLStarpharma completes A$32 million placement, SPP to follow
16/11/11	PRICE SENSITIVE	125.11KB	Share
SPLTrading Halt
14/11/11	PRICE SENSITIVE	52.38KB	Share
SPLResults of Meeting
10/11/11		37.18KB	Share
SPLAGM Chairman's address and CEO presentation
10/11/11		1.67MB	Share
SPLAppendix 4C - quarterly
27/10/11	PRICE SENSITIVE	165.23KB	Share
SPLNotice of Annual General Meeting/Proxy Form
10/10/11		595.26KB	Share
SPLStarpharma secures FDA agreement on BV treatment Phase 3
10/10/11	PRICE SENSITIVE	150.94KB	Share
SPLMs Zita Peach appointed non-executive director
26/09/11		138.5KB	Share
ACR +ALD ALK API ASZ BKY BSL CCP CNP CPB ATT DCG K2P FML ETM GMG HIL HUN IDL IFN ILU MCP MCR MEO MTU NDO OST PPT SRS IMM QUB RHG SFH SPL SSN STB TGA TGS ZSPSandP Indices Announces September Quarterly Rebalance
09/09/11	PRICE SENSITIVE	62.33KB	Share
SPLAppendix 3B
07/09/11		82.8KB	Share
SPLStarpharma Elevated to Standard and Poor's ASX 300 Index
06/09/11		145.28KB	Share
SPLStarpharma presents at Macquarie investor event
31/08/11		2.22MB	Share
SPLAnnual report and full year financial results
29/08/11	PRICE SENSITIVE	1.48MB	Share
SPLAppendix 3B
24/08/11		82.8KB	Share
SPLGSK awarded funds for dermal treatment with SPL's dendrimers
22/08/11	PRICE SENSITIVE	47.49KB	Share
ANN +SPLSPL terminates Reckitt agreement and signs with Ansell
17/08/11	PRICE SENSITIVE	196.49KB	Share
SPLSPL Commences VivaGel Bacterial Vaginosis Prevention Study
15/08/11	PRICE SENSITIVE	173.03KB	Share
SPLAppendix 3B
09/08/11		67.61KB	Share
SPLAppendix 4C - quarterly
28/07/11	PRICE SENSITIVE	155.22KB	Share
SPLShareholder Update July 2011
26/07/11		1.15MB	Share
SPLPartners of bacterial vaginosis at increased risk of HIV
19/07/11		142.16KB	Share
SPLAppendix 3B
13/07/11		70.35KB	Share
SPLStarpharma advances agrochemical program
12/07/11	PRICE SENSITIVE	243.24KB	Share
SPLAdvances leading cancer therapeutic in drug delivery program
29/06/11	PRICE SENSITIVE	251.98KB	Share
SPLAppendix 3Z
20/06/11		102.8KB	Share
SPLResignation of Director
20/06/11		133.48KB	Share
SPLAppendix 3B
14/06/11		62.4KB	Share
SPLStarpharma Audio Broadcast
24/05/11		88.08KB	Share
SPLVivaGel Demonstrates Efficacy in Bacterial Vaginosis
23/05/11	PRICE SENSITIVE	172.31KB	Share
SPLAppendix 3B
19/05/11		62.53KB	Share
SPLVivaGel Coated Condom Licence Agreement with Okamoto Japan
10/05/11	PRICE SENSITIVE	188.75KB	Share
SPLAppendix 4C - quarterly
27/04/11	PRICE SENSITIVE	153.36KB	Share
SPLAppendix 3B
01/04/11		62.41KB	Share
SPLChange in substantial holding
29/03/11		86.61KB	Share
SPLAppendix 3B
29/03/11		61.77KB	Share
SPLShareholder Update March 2011
29/03/11		530.89KB	Share
SPLCompletes enrolment for Phase 2 study of VivaGel for BV
23/03/11	PRICE SENSITIVE	149.02KB	Share
SPLAppendix 3B
22/03/11		64.2KB	Share
SPLChange in substantial holding
18/03/11		85.49KB	Share
SPLSPL presents at ASX Emerging Growth Conference
10/03/11		2.08MB	Share
SPLAppendix 3B
07/03/11		69.81KB	Share
SPLSPL to expand agricultural program through $250,000 funding
03/03/11	PRICE SENSITIVE	140.04KB	Share
SPLHalf Yearly Report and Accounts
21/02/11	PRICE SENSITIVE	705.75KB	Share
SPLAppendix 3B
17/02/11		65.05KB	Share
SPLChange in substantial holding
16/02/11		86.23KB	Share
SPLAppendix 3B
14/02/11		62.67KB	Share
SPLResponse to ASX Query
09/02/11	PRICE SENSITIVE	91.14KB	Share
SPLAppendix 3B
03/02/11		67.64KB	Share
SPLAppendix 3B
01/02/11		65.34KB	Share
SPLAppendix 4C - quarterly
31/01/11	PRICE SENSITIVE	59.55KB	Share
SPLChange of Director's Interest Notice
10/01/11		32.5KB	Share
SPLAppendix 3B
10/01/11		65.93KB	Share
SPLAppendix 3B
23/12/10		67.12KB	Share
SPLAppendix 3B
20/12/10		68.29KB	Share
SPLRevised Securities Trading Policy
16/12/10		72.21KB	Share
SPLChange of Director's Interest Notice - Dr J Fairley
15/12/10		17.03KB	Share
SPLAppendix 3B
10/12/10		67.8KB	Share
SPLAppendix 3B
02/12/10		67.7KB	Share

REFRESH

First 6 7 8 9 10

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$66.89K	513.9K

Buyers (Bids)

No.	Vol.	Price($)
4	221560	12.5¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	224531	9

View Market Depth

No.	Vol.	Price($)
4	221560	0.125
3	120252	0.120
3	138350	0.115
2	9099	0.110
3	106433	0.105

Price($)	Vol.	No.
0.135	224531	9
0.140	155588	4
0.145	65835	6
0.150	175000	3
0.155	74523	3

Last trade - 13.53pm 08/09/2025 (20 minute delay)


Last 13.0¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
13.0¢	13.3¢	12.5¢	284444
Last updated 13.53pm 08/09/2025 ?

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories

STARPHARMA HOLDINGS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories

Corporate Spotlight
Not Yet Available